肿瘤免疫治疗的新靶抗原——NY-ESO-1
摘要
NY ESO 1为CTA家族中的一种 ,是目前免疫原性最强的肿瘤抗原之一 ,有望成为用于肿瘤免疫治疗的新靶疫苗。本文就其基因与蛋白、表达与机理、抗原肽及免疫治疗等作一综述。
出处
《中国组织化学与细胞化学杂志》
CAS
CSCD
2003年第2期214-217,共4页
Chinese Journal of Histochemistry and Cytochemistry
基金
广西省自然科学基金 (No .0 2 2 90 32 )
参考文献25
-
1Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autogous antibody screening. Proc Natl Acad Sci U SA, 1997, 94 (5). 1914-1918.
-
2Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancertestis antigen NY-ESO-1 : definition of human histocompatibility leukocyte antigen (HLA) -A2-binding peptide epitopes. J Exp Med, 1998, 187 (2): 265-270.
-
3Chen YT, Boyer AD, Viars CS, et al. Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet Cell Genet, 1997, 79 (3--4) : 237-240.
-
4Schultz-Thater E, Noppen C, Gudat F, et al. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer, 2000, 83 (2):204-208.
-
5Haffner AC, Tassis A. Zepter K, et al. Expression of cancer/testis antigens in cutaneous T cell lymphomas.Int J Cancer, 2002, 97 (5): 668-670.
-
6Jungbluth AA, Antonescu CR, Busarn KJ, et al.Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CTT. Int J Cancer, 2001, 94 (2) : 252-256.
-
7Lim SH, Austin S, Owen-Jones E, et al. Expression of testicular genes in haematological malignancies. Br J Cancer, 1999, 81 (7): 1162-1164.
-
8Old LJ. Cancer/testis (CT) antigens -a new link between gamotogenesis and cancer. Cancer Immunity,2001, 1:1.
-
9Coral S, Sigalotti L, Aaltomonte M, et al. 5-aza-2'-deoxycytidine-indueed expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res, 2002, 8 (8):260-265.
-
10Jager E, Stoekert E, Zidianakis Z, et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with dinical events. Int J Cancer, 1999, 84 (5): 506-510.
-
1高峰,谷俊朝.热休克蛋白在乳腺癌发病机制及预后的意义[J].国外医学（外科学分册）,2005,32(4):283-286. 被引量：1
-
2陈君敏.树突状细胞与肿瘤的免疫治疗[J].福建医科大学学报,2000,34(4):407-410.
-
3张卉,索智敏,白玉,马许辉,杨德生.西妥昔单抗联合化疗靶向治疗食管癌的疗效[J].中国老年学杂志,2015,35(19):5536-5537. 被引量：7
-
4周慧,凌红阳,吴文璎,郑玉双.NY-ESO-1在喉鳞状细胞癌中的表达及意义[J].江苏医药,2015,41(3):332-333. 被引量：1
-
5杨碧辉,梁利斌.MAGE—A和NY—ESO-1的表达与子宫颈癌临床病理特征及预后关系探讨[J].浙江临床医学,2013,15(8):1134-1136. 被引量：2
-
6武翠玲.联合检测癌胚抗原肿瘤抗原199甲胎蛋白在胃癌中的临床价值[J].山西医药杂志（下半月）,2013,42(2):214-215. 被引量：2
-
7胡其仓,毕晓勇.3例等密度原发性肝癌CTA的诊断[J].医用放射技术杂志,2002(4):76-76.
-
8徐立,樊代明,金伯泉.肿瘤抗原研究的启示[J].医学与哲学,2000,21(3):39-40. 被引量：2
-
9杨进益,章咏裳.膀胱移行细胞癌增殖细胞核抗原表达的研究[J].中华泌尿外科杂志,1996,17(4):219-221. 被引量：7
-
10韩刚,于继云,高江平.以PSCA为靶点的前列腺癌免疫治疗的研究进展[J].军医进修学院学报,2009,30(2):225-226. 被引量：1
